Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma
- 1 January 1995
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 13 (2) , 143-147
- https://doi.org/10.1007/bf00872863
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A Phase II Trial of Merbarone (NSC 336628) as Salvage Therapy for Squamous Cell Carcinoma of the CervixAmerican Journal of Clinical Oncology, 1995
- Phase II Trial of Merbarone in Pancreatic CarcinomaAmerican Journal of Clinical Oncology, 1993
- Phase II Study of Taxol, Merbarone, and Piroxantrone in Stage IV Non-Small-Cell Lung Cancer: The Eastern Cooperative Oncology Group ResultsJNCI Journal of the National Cancer Institute, 1993
- A Phase II Study of Merbarone in Patients with Adenocarcinoma of the PancreasCancer Investigation, 1993
- Phase II trial of merbarone in soft tissue sarcomaInvestigational New Drugs, 1992
- Effect of specific enzyme inhibitors on replication, total genome DNA repair and on gene-specific DNA repair after UV irradiation in CHO cellsMutation Research/DNA Repair, 1991
- Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase IIBiochemistry, 1989
- Merbarone: an antitumor agent entering clinical trialsInvestigational New Drugs, 1987
- Initial mechanistic studies with merbarone (NSC 336628)Biochemical Pharmacology, 1985
- 5-(N-phenylcarboxamido)-2-thiobarbituric acid (NSC 336628), a novel potential antitumor agentBiochemical Pharmacology, 1985